Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Olorofim in Healthy Males
NCT02394483Phase 1Completed
- Sponsor
- F2G
- Start
- Oct 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of olorofim in invasive aspergillosis (IA) (10 cohorts), sponsored by F2G. Primary endpoint: Safety (Adverse events) at 10 days. Started Oct 2015; status: completed.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT02394483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02394483.